> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Hold Lifted on Immunome Covid Antibody Cocktail
- URL: https://www.fdaweb.com/hold-lifted-on-immunome-covid-antibody-cocktail/
- Published: 2022-03-11T12:00:00.000Z
- Updated: 2026-09-14T17:36:10.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5151350

FDA has lifted an Immunome clinical hold on its antibody cocktail (IMM-BCP-01) for treating Covid-19\. The hold was placed in early January, when the agency requested further information on the preparation and administration of IMM-BCP-01 at clinical sites.

IMM-BCP-01 is a three-antibody cocktail targeting non-overlapping regions of the Covid-19 spike protein, including “highly conserved, subdominant epitopes, which elicits both ACE2 and non-ACE2 dependent neutralization and induces natural viral clearance mechanisms, such as antibody dependent cellular cytotoxicity, complement activation and phagocytosis,” the company says. Immunome plans to soon begin a placebo-controlled dose escalation study of IMM-BCP-01 in Covid-infected patients.